Using special peptides to speed up healing of pressure ulcers
Official title: Regenerative peptide therapy to accelerate pressure ulcer healing
Funded at Adepthera, LLC · NIH-11006211 · Data updated 2026-11-12
This study is testing a special gel that helps heal bed sores by improving blood flow and tissue repair, and it's being tried out on older diabetic mice to see how well it works compared to a current approved treatment.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Adepthera, LLC NIH-funded |
| Lab location | 1 site (Palo Alto, United States) |
| Project start | September 15, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $367,577 |
| NIH project number | 1R43AG090115-01 |
| Project ID | NIH-11006211 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are elderly patients or those with diabetes who are at risk of developing pressure ulcers.
✕Less likely to help
Patients who do not have pressure ulcers or those with acute wounds may not benefit from this research.
What this research studies
This research investigates the use of super-agonistic analogs of adrenomedullin (ADM) and calcitonin gene-related peptide (CGRP) to enhance the healing of pressure ulcers, also known as bed sores. The approach involves creating a gel that self-assembles at the wound site, allowing for localized treatment that improves blood circulation and promotes tissue regeneration. The therapy is designed to be administered weekly or biweekly, targeting aging diabetic mice to determine the most effective formulation and dosage. The study aims to compare the effectiveness of this new gel with an existing FDA-approved treatment for wound care.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly accelerates the healing of pressure ulcers in patients.
How similar studies have gone: Previous research has shown promise with similar peptide therapies in enhancing wound healing, indicating potential for success in this approach.
Where this research is happening
-
Adepthera, LLC
Palo Alto, United States Active
Researchers
- Principal investigator: Hsu, Sheau-Yu Teddy — Adepthera, LLC
- Study coordinator: Hsu, Sheau-Yu Teddy
Related research
Other NIH-funded projects on the same topics.
-
Improving Diabetic Foot Ulcer Offloading with User-Friendly Cast Walker Design
A small pilot study to see how different removable cast walker designs affect daily use and healing of diabetic foot ulcers.
-
Parasitic Keratitis: Do Steroid Eyedrops Help or Harm?
A randomized trial will test whether adding a low-dose corticosteroid eyedrops after standard anti-amoebic therapy improves vision for people with Acanthamoeba keratitis.
-
Topical corticosteroids for acanthamoeba keratitis in adults
A randomized trial tests whether adding a mild steroid drop after standard anti-amoebic therapy helps improve vision and inflammation in people with acanthamoeba keratitis.
-
Corticosteroids for Acanthamoeba Keratitis in adults
A randomized trial tests whether adding a corticosteroid eye drop after standard anti-amoebic therapy helps improve vision in people with acanthamoeba keratitis.
-
Home-based exercise to help Veterans recover after healed diabetic foot ulcers
A home-based exercise program for Veterans who recently healed from a diabetic foot ulcer to improve walking and daily function.
-
Wearable insoles to help prevent diabetic foot ulcers
A wearable insole device will monitor foot pressure and temperature in adults with diabetes to help prevent foot ulcers and potential amputations.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.